Pilot Point, Texas—The National Reined Cow Horse Association (NRCHA) proudly announces that American Regent Animal Health, makers of Adequan i.m.® (polysulfated glycosaminoglycan), has expanded its support of the association, becoming the Official Joint Therapy of NRCHA. A valued partner since 2023, Adequan’s generous sponsorship supports the CowHorse+ entry system, as well as other NRCHA programs, services and events.
“We’re proud to recognize Adequan as the Official Joint Therapy of NRCHA,” said Patty Tiberg, NRCHA Director of Incentive & Sponsorships. “Their expanded commitment reflects a strong dedication to the performance horse industry and the long-term care of the equine athlete. We appreciate their continued support and look forward to growing our partnership.”
Reined cow horses work hard to achieve in our sport, competing in multiple events that require exceptional athleticism. Adequan and NRCHA share a commitment to keeping our horses comfortable and performing through all phases of life. For horses with equine arthritis, Adequan can help make that possible in multiple ways. Adequan has been proven to reduce inflammation, restore synovial joint lubrication, repair joint cartilage and reverse the disease process of arthirits.1,2
“For more than 30 years, supporting horses and riders has been our primary mission,” said Marjorie Lathrop, marketing director at American Regent Animal Health. “We’re excited to continue that legacy with NRCHA for another year as we help keep horses and their riders moving.”
Thanks to Adequan for keeping our horses entered up—both by presenting the CowHorse+ entry system and helping them stay ready to compete. Learn more about all NRCHA’s sponsors and partners at nrcha.com/sponsors/.
Adequan® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
INDICATIONS
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequan.com.
About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for over three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified American Regent portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
- Adequan® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
- Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
PP-AI-US-1274
